Skip to main content
. 2021 Aug 30;14(9):882. doi: 10.3390/ph14090882

Figure 1.

Figure 1

Schematic representation of tumor selection for immunohistofluorescence analysis. Glioblastoma (GBM); inclusion criteria: age between 18 and 70 years, primary glioblastoma and initially programmed for the standard Stupp protocol treatment; exclusion criteria: enrolled in clinical trial and non-standard treatment, including bevacizumab extensively off-label used in the study period in France.